紫杉醇联合顺铂用于局部晚期宫颈癌新辅助化疗近期疗效观察

The value of paclitaxel combined cisplatin in patients with local advanced cervical cancer

目的探讨术前紫杉醇联合顺铂化疗对局部晚期宫颈癌的近期疗效。方法选择病理确诊的12例Ⅰb^IIIb期局部晚期宫颈癌患者,行紫杉醇+顺铂化疗,紫杉醇135~175mg/m2,顺铂50~75mg/m2,此方案化疗2个疗程后手术,观察近期的疗效。结果临床近期有效率达83.3%,手术切除率达100%,所有手术患者均能顺利切除病灶并达到切缘距离病灶1cm以上。结论术前紫杉醇联合顺铂化疗可提高宫颈癌的近期疗效,患者能较好耐受。

Objective To investigate the efficacy of paclitaxel combined cisplatin in locally advanced cervical cancer be fore operation. Methods Twenteen patients dignosed by pathology with locally advanced cervical cancer in stage Ⅰb-Ⅲb were treated with paclitaxel 135 175 mg/m^2 over 3 hours and cisplatin50-75 mg/m^2 for 2 cycles and followed by operation. Results The overall response rate was 83.3%. The rate of surgery after chemotherapy was 100%. All patients underwent radical hysterectomy easily and the edge of surgical specimens between local primary tumor reached more than tcm. Conclusion The regimen of paclitaxel and cisplatin are effective and can be well-tolerated by patients with cervical cancer. It shows promising prospect in clinical application.